Annotation of rs3736228

Genotype CT is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype CC.

Response was measured by improvement in mean visual acuity, using either Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity tests. Visual acuity was measured at baseline and after three monthly intravitreal ranibizumab injections.

From Publication

Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology. 2012. Smailhodzic Dzenita et al.
PMID:22840423(opens in new window) DOI:10.1016/j.ophtha.2012.05.040(opens in new window)

Gene

LRP5

Variant

rs3736228

Phenotype Category

Efficacy

Association Significance

The study reports this association is not significant

PharmGKB ID

981755362

Score
More info on scoring

-1.75

Evidence for Clinical Annotations

This annotation has been used as evidence for the following clinical annotations.

    Study Parameters

    Study type

    cohort

    Study size

    388

    Association p-value

    = 0.96

    Allele frequency

    T=0.72

    Biogeographical group
    More info on groups

    European

    Population description

    elderly

    Age Group: 50 years of age or older. Specifically, 420 eyes of 397 patients were studied.

    Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.

    History

    Loading...